Skip to content
Screener

Generate Biomedicines, Inc. GENB Net Income

Net Income at other companies

BK
BKBK
$1.63B+33.8%
BK
BKBK
$1.63B+33.8%
Veradermics logo
VeradermicsMANE
-$27.23M-120%
GPA
General Purpose Acquisition Corp.GPAC
-$5.23M-37.4%
GPA
General Purpose Acquisition Corp.GPAC
-$5.23M-37.4%
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
-$2.54M+49.6%

Other financials

Income statement

See full
Revenue$6.3M-37.7%
Operating income-$71.6M-19.1%
EPS (diluted)-$0.52+73.2%

Balance sheet

See full
Cash & equivalents$135.4M-12.3%
Total debt$62.6M—
Total equity$456.0M+188%
Total assets$561.7M—

Cash flow

See full
Operating cash flow-$57.9M-18.9%
CapEx$933.0K+506%
Free cash flow-$58.9M-20.4%

Valuation

See full
Market cap$1.86B+19.8%
Enterprise value$1.78B—
P/S57.2×—

Profitability

See full
Operating margin-751.2%—
Net margin-685.9%—
FCF margin-756.9%—

Returns & leverage

See full
Return on equity2,979.4%—
Debt / equity0.1×—
Current ratio8.3×—

Where this comes from

Reported directly by Generate Biomedicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: Generate Biomedicines, Inc.’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 6:01 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336437

FAQ

What is Generate Biomedicines, Inc.'s net income?
Generate Biomedicines, Inc. (GENB) reported net income of -$67.26M in Q2 2026.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.

Ask your AI about Generate Biomedicines, Inc.'s net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude